Stock analysts at Craig Hallum assumed coverage on shares of Aspen Aerogels Inc. (NYSE:ASPN) in a research note issued on Tuesday. The firm set a “buy” rating on the stock.

A number of other brokerages have also recently weighed in on ASPN. Canaccord Genuity restated a “buy” rating and set a $8.50 target price on shares of Aspen Aerogels in a report on Thursday, August 4th. Zacks Investment Research cut shares of Aspen Aerogels from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. JPMorgan Chase & Co. reduced their target price on shares of Aspen Aerogels from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Friday, August 5th. Finally, Citigroup Inc. reduced their target price on shares of Aspen Aerogels from $6.50 to $6.00 and set a “buy” rating for the company in a report on Thursday, July 7th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $7.13.

Shares of Aspen Aerogels (NYSE:ASPN) opened at 4.96 on Tuesday. Aspen Aerogels has a 12-month low of $3.38 and a 12-month high of $8.87. The firm’s market capitalization is $102.09 million. The stock’s 50 day moving average price is $4.88 and its 200-day moving average price is $4.59.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/aspen-aerogels-inc-aspn-now-covered-by-analysts-at-craig-hallum.html

Aspen Aerogels (NYSE:ASPN) last issued its earnings results on Thursday, August 4th. The company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.02. The firm earned $27.70 million during the quarter, compared to analysts’ expectations of $30.99 million. Aspen Aerogels had a negative net margin of 3.14% and a negative return on equity of 3.35%. During the same period last year, the firm posted ($0.12) earnings per share. On average, equities analysts expect that Aspen Aerogels will post ($0.30) EPS for the current year.

In related news, Director Richard F. Reilly bought 10,000 shares of the firm’s stock in a transaction on Tuesday, August 23rd. The stock was bought at an average price of $4.82 per share, with a total value of $48,200.00. Following the purchase, the director now directly owns 36,178 shares of the company’s stock, valued at approximately $174,377.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William P. Noglows bought 20,000 shares of the firm’s stock in a transaction on Wednesday, August 24th. The shares were bought at an average cost of $4.98 per share, with a total value of $99,600.00. Following the purchase, the director now directly owns 46,178 shares in the company, valued at $229,966.44. The disclosure for this purchase can be found here. 14.70% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of ASPN. Goldman Sachs Group Inc. bought a new stake in shares of Aspen Aerogels during the first quarter worth about $115,000. Balter Liquid Alternatives LLC raised its stake in shares of Aspen Aerogels by 162.8% in the first quarter. Balter Liquid Alternatives LLC now owns 33,236 shares of the company’s stock worth $150,000 after buying an additional 20,590 shares during the period. Royce & Associates LP raised its stake in shares of Aspen Aerogels by 44.1% in the first quarter. Royce & Associates LP now owns 97,996 shares of the company’s stock worth $441,000 after buying an additional 30,011 shares during the period. Granite Investment Partners LLC raised its stake in shares of Aspen Aerogels by 93.9% in the first quarter. Granite Investment Partners LLC now owns 332,618 shares of the company’s stock worth $1,497,000 after buying an additional 161,112 shares during the period. Finally, Heartland Advisors Inc. bought a new stake in shares of Aspen Aerogels during the second quarter worth about $497,000. 76.10% of the stock is owned by institutional investors.

About Aspen Aerogels

Aspen Aerogels, Inc is an energy technology company that designs, develops and manufactures aerogel insulation used primarily in energy infrastructure facilities. The Company also performs contract research services for various federal and non-federal government agencies, including the Department of Defense, the Department of Energy and other institutions.

5 Day Chart for NYSE:ASPN

Receive News & Ratings for Aspen Aerogels Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels Inc. and related companies with MarketBeat.com's FREE daily email newsletter.